{
  "drug_name": "Ceftibuten",
  "tradename": "Cedax",
  "usage_and_dosing": {
    "general": [
      "Ceftibuten is a 3rd-generation oral cephalosporin used to treat AECB, otitis media and Streptococcus pyogenes tonsillitis/pharyngitis. It has poor activity against staphylococci and is only active against penicillin-susceptible strains of Strep. pneumoniae.",
      "Where available. No longer marketed in the U.S.",
      "For Penicillin cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview. See also Penicillin (Beta Lactam) Allergy Overview."
    ],
    "adult_dose": {
      "usual_dose": "400 mg po q24h"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "9 mg/kg/day (divided q12-24h)",
      "max_day": "1 gm"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "2.5",
    "half_life_esrd": "13",
    "dose_renal_function_normal": "400 mg po q24h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q24h. CrCl <10: 100 mg q24h",
    "hemodialysis": "100 mg q24h (dose AD on dialysis days)",
    "capd": "100 mg po q24h",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Treatment stopped due to adverse effects (2%), rash (rare), eosinophilia (5%), thrombocytopenia (rare), GI (6%), nausea/vomiting (2%), diarrhea (3%), C. difficile colitis, increased LFTs (rare), increased BUN/Creatinine (rare), headache (rare).",
    "For class-wide adverse effects, see Cephalosporins, Overview."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Cap (400 mg), oral susp (90 mg/5 mL, 180 mg/5 mL)",
    "food_recommendation": "All preps no food",
    "oral_absorption_percent": "80",
    "tmax_hr": "2.6",
    "peak_serum_conc_ug_ml": "15 (400 mg po, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "65",
    "volume_of_distribution_vd_l_kg_vf": "0.21 L/kg (V/F)",
    "avg_serum_half_life_hr": "2.5",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "73.7 (400 mg po, 0-inf)"
  },
  "major_drug_interactions": [
    "No significant interactions"
  ]
}
